Osborne C K, Drelichman A, Von Hoff D D, Crawford E D
Cancer Treat Rep. 1983 Dec;67(12):1133-5.
Thirty-seven patients with metastatic prostate cancer refractory to endocrine therapy were treated in a phase II trial of mitoxantrone. Starting doses were 12 and 10 mg/m2 iv every 21 days for good-risk and poor-risk patients, respectively. Of the 35 evaluable patients, two had objective partial regression and five had stable disease. Response duration ranged from 7 to 17+ months. The drug was very well tolerated by these elderly patients; myelosuppression was the major toxic effect. We conclude that mitoxantrone has modest activity and acceptable toxicity in patients with advanced prostate cancer.
37例对内分泌治疗耐药的转移性前列腺癌患者接受了米托蒽醌的II期试验治疗。对于低危和高危患者，起始剂量分别为每21天静脉注射12和10mg/m²。在35例可评估患者中，2例出现客观部分缓解，5例病情稳定。缓解持续时间为7至17个多月。这些老年患者对该药物耐受性良好；骨髓抑制是主要的毒性作用。我们得出结论，米托蒽醌在晚期前列腺癌患者中具有适度的活性和可接受的毒性。
